Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.49 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
| ▸ | SRC | P12931 | 3/20 | 0.48 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.48 |
| ▸ | TLK1 | Q9UKI8 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | YES1 | P07947 | 2/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | STK25 | O00506 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.48 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13755220 | 1.00 | KDR (0.58) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL31672422 | 1.00 | KDR (0.58) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL13755195 | 0.96 | KDR (0.62) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL31672537 | 0.96 | KDR (0.62) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL2113630 | 0.96 | KDR (0.62) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL13755186 | 0.93 | PDGFRB (0.56) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL2117372 | 0.93 | PDGFRB (0.56) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL13755203 | 0.91 | PDGFRB (0.55) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL31672424 | 0.91 | PDGFRB (0.55) | KDRPDGFRBFGFR1EGFRTLK2 | |
| SCHEMBL2116256 | 0.91 | PDGFRB (0.55) | KDRPDGFRBFGFR1EGFRTLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | KDR 395/4885PDGFRB 555/4885FGFR1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.